Straits Times Index
3,308.38 +11.49 (+0.35%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,423.73 +216.60 (+1.19%) FTSE 100
8,172.15 +50.91 (+0.63%) Bitcoin USD
59,827.50 +2,426.86 (+4.23%) CMC Crypto 200
1,283.17 +12.43 (+0.98%)
Deciphera Pharmaceuticals, Inc. (DCPH)
After hours:
| Previous close | 25.36 |
| Open | 25.40 |
| Bid | 25.33 x 100 |
| Ask | 25.41 x 100 |
| Day's range | 25.34 - 25.47 |
| 52-week range | 9.90 - 25.47 |
| Volume | |
| Avg. volume | 1,491,780 |
| Market cap | 2.087B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
- Reuters
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.
- Benzinga
Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?
On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera brings specialized research and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities. In addition to QINLOCK – Deciphera’s switch-control inhibitor for the treatment of fourth-li
